LADA / Type 1.5 Reversal: Suresh M. (Delhi, 62) — Fasting Sugar 210 → 105 mg/dL
Patient profile
- Name: Suresh M.
- Age: 62 · Sex: Male
- City: Delhi, India
- Diagnosis: Latent Autoimmune Diabetes in Adults (LADA / Type 1.5)
- Co-morbidities at intake: mild dyslipidaemia
Starting numbers
- Fasting glucose: 210 mg/dL
- HbA1c: 8.9%
- Anti-GAD antibodies: elevated (autoimmune confirmed)
- Medications: Insulin glargine 14u + Metformin
Personalised protocol
For LADA the priority is beta-cell preservation, not just glucose-lowering. UrCare combined PancreReViv + BetaReViv + GlucoLow, a strict low-load diet to minimise post-prandial spikes, and gentle resistance training. The hybrid approach addresses both autoimmune attack (via BetaReViv) and insulin sensitivity (via GlucoLow).
Timeline
- Week 4: Fasting glucose stabilised under 140 mg/dL.
- Month 3: Insulin glargine reduced from 14u → 6u.
- Month 5: Fasting glucose 105 mg/dL; HbA1c at 6.4%.
Outcome
Fasting glucose moved from 210 → 105 mg/dL. Insulin requirement cut by >55%. Honeymoon phase preserved with continuing immune-supporting protocol.
In Suresh's words
"Fasting sugar consistently under 110 now. The diet plan and supplements were game-changers. My doctor couldn't believe the improvement."
LADA reversal is about extending the honeymoon — not curing autoimmunity. Continued protocol adherence is essential. Consult your endocrinologist before reducing insulin.
